On Friday, Shares of BlackBerry Ltd (NASDAQ:BBRY), lost -3.68% to $7.33.
BlackBerry Limited declared that it has reached a definitive agreement to acquire AtHoc. Terms of the transaction were not revealed.
AtHoc is a leading provider of secure, networked crisis communications. Its software platform enables people, devices and organizations to exchange critical information in real time during business continuity and life safety operations. The AtHoc platform will integrate with BlackBerry’s enterprise portfolio and trusted global network to offer customers new capabilities for safety, security and mission-critical business communication. The acquisition will enable AtHoc to expand globally and enhance scale, in addition to deliver new applications on a secure platform for mass communication. For example, new applications may comprise integrating AtHoc solutions with BBM Meetings during an alert to enable live video feeds or transmit messages to provide real-time partnershipby leaders and decision makers.
BlackBerry Limited provides wireless communications solutions worldwide. The company offers BlackBerry wireless solutions, which comprise the sale of BlackBerry handheld devices; and the provision of data communication, and compression and security infrastructure services enabling BlackBerry handheld wireless devices to send and receive wireless messages and data.
Shares of Cepheid (NASDAQ:CPHD), declined -10.60% to $56.26, during its last trading session.
Cepheid stated revenue for the second quarter of 2015 of $132.5 million, representing growth of 14% from $116.5 million for the second quarter of 2014. Net loss was $(16.7) million, or $(0.23) per share, which compares to net loss of $(9.8) million, or $(0.14) per share, in the second quarter of 2014.
Not taking into account stock-based compensation expense, amortization of debt discount and transaction costs, and amortization of purchased intangible assets, non-GAAP net loss for the second quarter of 2015 was $(4.5) million, or $(0.06) per share. This compares to non-GAAP net income of $2.3 million, or $0.03 per share, in the second quarter of 2014.
Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures.
Finally, ImmunoGen, Inc. (NASDAQ:IMGN), ended its last trade with -4.08% loss, and closed at $17.41.
ImmunoGen, declared that the Company will host a conference call at 8:00 a.m. ET on Friday, July 31, 2015, to talk about ImmunoGen’s financial results for the three-month period and fiscal year ended June 30, 2015 and its guidance for its 2016 fiscal year. Administration also will provide an update on the Company.
ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
